Konstantinion Research Center of Molecular Medicine & Biotechnology


: Apr 10, 2020


Looking for Partnership
About Me

KRC History

Konstantinion Research Center of Molecular Medicine & Biotechnology non-profit Foundation (KRC) was founded on 4/12/06 in Thessaloniki, Greece with main goal the promotion of research with the higher scientific, modern techniques, and moral criteria, as well as successful collaborations in national and international level. KRC is an innovative multicenter of creativity, which intends to promote research, educate, and collaborate by organizing seminars and cultural events, and participating in revolutionary research programs. Since 2010 KRC had its own scientific journal, but its publication has been postponed, because of other KRC essential priorities, related to the core strengthening and KRC development in human resources and test-methodologies’ practical priorities (time limitations). One of our next targets is to restart the publication of KRC journal, entitled as Health & Research. There have been published several interesting articles in its volumes as listed below through hyperlinks:

ü  Research & Health, volume 2, issue 3, June 2011

ü  Research & Health, volume 1, issue 2, November 2010

ü  Research & Health, volume 1, issue 1, May 2010, a modern magazine of Konstantinion Research Center

 

Within the context of KRC sustainability, there are several services, products, biological applications and devices that are available to KRC members and health professionals for social, professional and scientific utilization.

 

Scope

The founder of KRC is already member in editorial board and reviewer of 10 international journals and will present soon the course of Natural Regulating Medicine. Some goals or the foundation are the following:  

·         To collaborate with pharmaceutical or biomedical companies that have as intension the discovery of new drugs or biological supplements locally and internationally.

  • To organize and participate in seminar/conferences for the information of the public, and to propose scientific solution for prevention of the human health.
  • To collaborate with all the medical specialties of modern medicine in molecular, biological, genetic, bioresonance, and biotechnological level.
  • To help and train new researchers, scientists, health practitioners with new scientific techniques for better health welfare.
  • To develop new therapeutic and diagnostic protocols for prevention of human chronic, genetic and degenerative diseases.
  • To develop research team with new and excellent scientists to work in all the above goals of the Research Center.
  • To collaborate with other sciences as chemistry, quantum physics and mechanics, and to explore situations in matter, life in molecular and biotechnological level (nanobiotechnology)

 

KRC Participation in Congresses

·         6th Annual Global Cancer Conference PCS (Athens November 14/15/ 2019)

·         13th International Symposium for Immunology of Reproduction 2012

·         13th International Congress of Immunology 2007

·         33rd Panhellenic Medica Congress – Athens 2007

·         4th International Conference 2006 (Biological Effects of EMFs)

·         16th European Conference of Immunology 2006

·         31st European FEBS Conference 2006

 

KRC awarded members

  • Award for the best original research (2008)
  • Award of Hans-Heinrich Reckeweg (2005)

 

Currency

Our newsletters and recent announcements can be found at ;lang=en

 

KRC’s future plans in the Sector of Medical Research & Innovation

1.) Diagnostic evaluation with 25 monoclonal antibodies for cancer patients-an innovation for the planet These 25 monoclonal antibodies can be used in daily practice by clinicians to manage cancer patients in order to extend their life and give them much more quality in their daily routine. These antibodies cover specific pathways for cancer in terms of its metabolism, multiplication, EMT, metastasis, adhesion, and survival, which have been proven the last years and can be essential factors in the daily practice in order to manage the cancer patient with more targeted and individualized therapies. This project is mandatory to achieve international collaborations with high level scientists for the benefit of the cancer patients. Some of these antibodies are the following in all pathways of cancer and already have been tracked and ready to be set in labr: Multiplication: Bcl2, VEGF-A, VEGF-C, VEGF-D, Epithelial Mesenchymal transition: MMP9, WNT, TGF-b Metastasis: NOX2, OCT4, LOX1, Bcl2, STAT3 Adhesion: PDGF-AA, PDGF-AB, PDGF-BB, PAI1. Survival: CD36, CD47, CD44, survivin.

2.) The innovative new diagnostic markers for Alzheimer’s disease-new alternative treatments Our clinical-laboratorial team after several years of searching have found from the bibliography and selected innovative biomarkers that will make the difference in early prognosis of this disease and also to giver therapies with no side effects in order to stop or decrease the progression of this disease. Our center is in the development of the materials and seeking the pricing for the reagents in order to set them in the lab.

Keywords and matching areas:

 Alternative Therapies
 Medical equipment
 Biological Sciences
 Innovation & Research
 Medical Biotechnology
 Education and Training
 Higher Education
 European Voluntary Services
 Biology
 Research

Ideas in Progress
No ideas yet!
Favourite Calls
No Favourite calls!